close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Nearly 15 percent of Fenwick partners named America's Leading Lawyers for Business by Chambers USA and Chambers Global
  • Selected as a "Go-To" law firm by in-house legal departments at Fortune 500 companies in Corporate Counsel magazine
  • Named to The National Law Journal's inaugural "Intellectual Property Hot List" for outstanding patent, copyright, trademark and IP litigation services

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

PUBLICATION DETAILS

Life Sciences Financing Survey - First Half, 2013

September 16, 2013

Trends in Terms of U.S. Life Science Venture Financings
(First Half, 2013)

Overview of Fenwick & West Results

While the first half of 2013 saw a surge in initial public offerings (IPOs) by venture-backed biopharma companies, the overall financing environment for privately held life science companies remains slow.

The average valuation increase for life science companies receiving venture capital financing during the first half of 2013 was roughly even with 2012 results, and the percentage of “up round” financings declined slightly. Fundraising by life science venture capitalists continued to decline as well.

Key observations and highlights include the following:

  • Up rounds outpaced down rounds 46% to 21% during the first half of 2013, representing a modest decline from 2012 results.
  • The average round-to-round price increase for companies receiving venture financing, as measured by the Fenwick & West Life Science Venture Capital Barometer™, was 25% in Q1 of 2013 and 15% during Q2, bringing the four-quarter moving average to 22%. For comparison, average Barometer results for 2012 were 23%.
  • Investments in venture-backed life science companies (as reported by VentureSource and the MoneyTree Report) remain on par with 2012 levels. Total dollar investment during the first half of 2013 was in line with
    five-year historical averages, but the number of deals was down by more than 10%.
  • Fundraising by life science venture capitalists continued to decline during the first half of 2013. Our analysis indicates that the percentage of VC fundraising allocable to life sciences has declined from 27% of funds raised in 2008 to 11% of funds raised in the first half of 2013. In absolute dollar terms, we estimate that fundraising has fallen from an average of $7.8 billion/year in 2007 and 2008 to $1.3 billion in the first half of 2013 (representing an annualized rate of $2.6 billion/year).
  • Life science M&A activity during the first half of 2013 was slower in comparison to results reported for the same period in 2012.
  • The life science IPO market was exceptionally strong during the first half of 2013. A total of 15 U.S.-based venture-backed life science companies (14 in the biopharma sector) went public during the period, raising a total of $1.1 billion. Public market stock indexes for life science companies also significantly outpaced broader market averages.
  • With regard to venture financing deal terms, senior and participating liquidation preferences remained a relatively common feature of life science venture financings during the first half of 2013, appearing in 45% (for senior preferences) and 56% (for participating preferences) of the financings we reviewed. This is in line with results observed during 2012, although the percentage of deals with participating liquidation preferences has declined modestly.
  • Pay-to-play provisions are also a common feature of life science venture financings, appearing in 26% of financings during the first half of 2013, in comparison to an average of 21% of 2012 financings. A substantial majority of these pay-to-play provisions apply only to additional closings of the current financing round, indicating that they were implemented in connection with tranched or milestone-based financing structures.

 

 

View the full version of the First Half, 2013 Life Sciences Survey (PDF).

​ ​​​​​​​​